FDA Expanded Use for LOBO Vascular Occlusion System
The FDA granted an expanded indication for the LOBO Vascular Occlusion System, covering additional venous treatments.
Updated on Oct. 8, 2026 in Stroke
Live Poll
Should the FDA accelerate the approval process for new medical device indications?
The U.S. Food and Drug Administration has granted an expanded indication for the LOBO Vascular Occlusion System. This regulatory decision now allows the device to be used in peripheral veins.
Why it matters
The expansion permits physicians to utilize the device for a broader range of complex conditions, including pelvic venous disease and portal hypertension. This update provides clinicians with new options for treating venous system pathologies.
The FDA approval marks a change in clinical indication for the medical device. The device remains cleared for treating pelvic venous disease and portal hypertension, with the usage now extended into peripheral veins.
The players
U.S. Food and Drug Administration
The federal agency responsible for protecting public health by ensuring the safety, efficacy, and security of medical devices and human drugs.
Okami Medical
The Aliso Viejo, California-based medical technology company that manufactures the LOBO Vascular Occlusion System.
The details
The FDA expanded the clinical indication for the LOBO Vascular Occlusion System to improve access for patients requiring specialized venous intervention. The device is specifically designed to address complex vascular issues such as pelvic venous disease and portal hypertension.
Timeline
October 7, 2026: The FDA granted the expanded indication for the LOBO system.
Deeper Dive
This regulatory update follows the established protocols of the FDA's 510(k) medical device clearance process. The expansion reflects a broader trend of repurposing existing vascular occlusion technologies for diverse venous applications.
This expansion increases the clinical options available for patients suffering from pelvic venous disease or portal hypertension. Patients may now benefit from the use of this device in peripheral veins as determined by their attending vascular specialist.
The takeaway
The FDA authorization signals an evolution in the utility of specialized vascular occlusion tools for complex venous treatments. Healthcare providers can now incorporate this device into a wider array of peripheral vascular care plans.
Further reading
For more context on vascular health and intervention, visit the Stroke section.
Source note: This article includes information reported by Gillette News Record.
Live Poll
Should the FDA accelerate the approval process for new medical device indications?
